Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Jan 25, 2024 1:52pm
103 Views
Post# 35845470

RE:CG Oncology

RE:CG OncologyCG is now trading. 

IPO at $19, and trading on opening day above $30.

Current market cap of CGON is above $1.5 BIllion U.S.

Current market cap of ONCY is less than $100 Million U.S.

Market values CGON at more than 15 times the value of ONCY.

Even more telling, on a day when oncolytic viruses are in the spotlight and we have our first Oncoltyic Virus Unicorn, at a time when one might expect valuations of all oncolytic virus companies to rise due to interest in the field... 

ONCY is up 5 CENTS.

Recall, back on December 13th, 2023 the CEO of Oncolytics Biotech announced to the world that his company's fair value was less than $1.45 per share. 

ONC desparately needs and new CEO.

With the firing of MC, ONC's stock might double in price. 
<< Previous
Bullboard Posts
Next >>